Results 171 to 180 of about 1,030,121 (356)
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
The Common Form of Niacin Amide Deficiency Disease: Aniacinamidosis.
, 1943 openalex +2 more sources
Investigation of the α‐Galactosidase Deficiency in Fabry's Disease Using Antibodies against the Purified Enzyme [PDF]
, 1974 P. J. G. M. Rietra +4 more
openalex +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source
Control of HIV across the WHO European region: progress and remaining challenges
The Lancet Regional Health. EuropeSummary: Despite the ambitious global goal to control HIV transmissions by 2030, more than 30% of people with HIV from the WHO European Region show persistent transmissible levels of the virus.
Miłosz Parczewski +8 more
doaj
Molecular Oncology, EarlyView.TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach +8 more
wiley +1 more source
Vitamin E deficiency and thrombocytosis in Caffey's disease. [PDF]
, 1976 Barry R. Keeton
openalex +1 more source
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology, EarlyView.The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source